Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss

Journal of Clinical Oncology

Volumn 30, Issue 33, 2012, Pages

  Voskens, Caroline ^a   Cavallaro, Alexander ^a   Erdmann, Michael ^a   Dippel, Olga ^a   Kaempgen, Eckhart ^a   Schuler, Gerold ^a   Schuler Thurner, Beatrice ^a   Heinzerling, Lucie ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DIPYRONE; FOTEMUSTINE; IPILIMUMAB; NALOXONE; PACLITAXEL; SORAFENIB; TILIDINE;

ADULT; ARTICLE; BACKACHE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HEARING IMPAIRMENT; HUMAN; KIDNEY FAILURE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RASH; REGRESSION ANALYSIS; SPINAL CORD METASTASIS; TREATMENT RESPONSE; VIRUS PNEUMONIA; VISUAL IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLINDNESS; CTLA-4 ANTIGEN; FEMALE; HEARING LOSS; HUMANS; MELANOMA; MIDDLE AGED; PNEUMONIA, MYCOPLASMA; RENAL INSUFFICIENCY; SPINAL CORD NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84869455987     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.4359     Document Type: Article

References (14)

1. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
2. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-4717, 2003
3. Friedline RH, Brown DS, Nguyen H, et al: CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206:421-434, 2009
4. Chmiel KD, Suan D, Liddle C, et al: Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29:e237-e240, 2011
5. Fadel F, El Karoui K, Knebelmann B: Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:211-212, 2009
6. Wilgenhof S, Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 22:991-993, 2011
7. O'Day S, Weber JS, Wolchok JD, et al: Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. J Clin Oncol 29, 2011 (suppl; abstr 8554)
8. Harmankaya K, Erasim C, Koelblinger C, et al: Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 28:1140-1144, 2011
9. Attia P, Phan GQ, Maker AV, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053, 2005
10. Weber J: Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58:823-830, 2009
11. Weber JS, Amin A, Minor D, et al: Safety and clinical activity of Ipilimumab in melanoma patients with brain metastases: Retrospective analysis of data from a phase II trial. Melanoma Res 21:530-534, 2011
12. Downey SG, Klapper JA, Smith FO, et al: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681-6688, 2007
13. Hodi FS, Oble DA, Drappatz J, et al: CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastasis to the CNS. Nat Clin Pract Oncol 5:557-561, 2008
14. Schartz NE, Farges C, Madelaine I, et al: Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 20:247-250, 2010